P F
11 dic, 2023

Omnitrope - Growth Hormone Coverage Update

A formulary change for BCBSRI Commercial plans is being made in response to the current growth hormone shortage. 

Several plans currently cover Norditropin and Genotropin as a preferred brand growth hormone. As of 1 de diciembrest, 2023, Omnitrope was added to coverage as an additional preferred brand growth hormone option. Norditropin and Genotropin remain covered as a preferred brands. Manufacturers estimate that growth hormone shortages will continue through 2023.

If your patients have any questions about this change, here are some resources you can offer: